Mukherjee N - Search Results

1

To be an ally or an adversary in bladder cancer: the NF-κB story has not unfolded.

Mukherjee N, Houston TJ, Cardenas E, Ghosh R. Mukherjee N, et al. Carcinogenesis. 2015 Mar;36(3):299-306. doi: 10.1093/carcin/bgu321. Epub 2014 Dec 27. Carcinogenesis. 2015. PMID: 25543121 Free PMC article. Review.

2

DNA Methylation and Flavonoids in Genitourinary Cancers.

Mukherjee N, Kumar AP, Ghosh R. Mukherjee N, et al. Curr Pharmacol Rep. 2015 Apr 1;1(2):112-120. doi: 10.1007/s40495-014-0004-8. Curr Pharmacol Rep. 2015. PMID: 26005633 Free PMC article.

3

SETD6 regulates NF-κB signaling in urothelial cell survival: Implications for bladder cancer.

Mukherjee N, Cardenas E, Bedolla R, Ghosh R. Mukherjee N, et al. Oncotarget. 2017 Feb 28;8(9):15114-15125. doi: 10.18632/oncotarget.14750. Oncotarget. 2017. PMID: 28122346 Free PMC article.

4

Efficacy of bacillus Calmette-Guérin Strains for Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Network Meta-Analysis.

Boehm BE, Cornell JE, Wang H, Mukherjee N, Oppenheimer JS, Svatek RS. Boehm BE, et al. Among authors: mukherjee n. J Urol. 2017 Sep;198(3):503-510. doi: 10.1016/j.juro.2017.01.086. Epub 2017 Mar 10. J Urol. 2017. PMID: 28286068 Free PMC article.

5

Role of immunotherapy in bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.

Mukherjee N, Svatek RS, Mansour AM. Mukherjee N, et al. Urol Oncol. 2018 Mar;36(3):103-108. doi: 10.1016/j.urolonc.2017.12.020. Epub 2018 Feb 9. Urol Oncol. 2018. PMID: 29429897 Free PMC article. Review.

6

Cancer Immune Therapy: Prognostic Significance and Implications for Therapy of PD-1 in BCG-Relapsing Bladder Cancer.

Mukherjee N, Svatek R. Mukherjee N, et al. Ann Surg Oncol. 2018 Sep;25(9):2498-2499. doi: 10.1245/s10434-018-6610-7. Epub 2018 Jul 3. Ann Surg Oncol. 2018. PMID: 29971674 Free PMC article. No abstract available.

7

Bacillus Calmette-Guérin treatment of bladder cancer: a systematic review and commentary on recent publications.

Mukherjee N, Wheeler KM, Svatek RS. Mukherjee N, et al. Curr Opin Urol. 2019 May;29(3):181-188. doi: 10.1097/MOU.0000000000000595. Curr Opin Urol. 2019. PMID: 30762672 Free PMC article.

8

CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation.

Reyes RM, Deng Y, Zhang D, Ji N, Mukherjee N, Wheeler K, Gupta HB, Padron AS, Kancharla A, Zhang C, Garcia M, Kornepati AVR, Boyman O, Conejo-Garcia JR, Svatek RS, Curiel TJ. Reyes RM, et al. Among authors: mukherjee n. J Immunother Cancer. 2021 Apr;9(4):e002051. doi: 10.1136/jitc-2020-002051. J Immunother Cancer. 2021. PMID: 33849925 Free PMC article.

9

Bladder tumor ILC1s undergo Th17-like differentiation in human bladder cancer.

Mukherjee N, Ji N, Tan X, Lin CL, Rios E, Chen CL, Huang T, Svatek RS. Mukherjee N, et al. Cancer Med. 2021 Oct;10(20):7101-7110. doi: 10.1002/cam4.4243. Epub 2021 Sep 8. Cancer Med. 2021. PMID: 34496133 Free PMC article.

10

γδ T Cells Support Antigen-Specific αβ T cell-Mediated Antitumor Responses during BCG Treatment for Bladder Cancer.

Ji N, Mukherjee N, Shu ZJ, Reyes RM, Meeks JJ, McConkey DJ, Gelfond JA, Curiel TJ, Svatek RS. Ji N, et al. Among authors: mukherjee n. Cancer Immunol Res. 2021 Dec;9(12):1491-1503. doi: 10.1158/2326-6066.CIR-21-0285. Epub 2021 Oct 4. Cancer Immunol Res. 2021. PMID: 34607803 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

424 results

Search Page